Somi Igbene, PhD, science writer —

Somi graduated from Imperial College London in 2011 with a PhD in cellular and molecular immunology. She worked as a medical writer at several medical communications agencies in London, including Core Medica. Besides science writing, Somi works as a registered associate nutritionist, helping adults and children improve their diets to prevent type 2 diabetes.

Articles by Somi Igbene

Gesynta Pharma Seeks OK to Assess GS-248 in Trials

Gesynta Pharma has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking approval to test its oral therapy, GS-248, in clinical trials with systemic sclerosis (scleroderma) patients. GS-248 is an experimental therapy being developed for conditions characterized by microvascular disease, including systemic sclerosis.